DR. EDWARD B RUBENSTEIN, MD
Osteopathic Medicine at Dryden Rd, Houston, TX
License number
Texas G2572
Category
Osteopathic Medicine
Type
Internal Medicine
Address
Address
2154 Dryden Rd, Houston, TX 77030
Phone
(713) 303-0154
Personal information
See more information about EDWARD B RUBENSTEIN at radaris.comName
Address
Phone
546 Stoneleigh Dr, Houston, TX 77079
4107 Tremont Ct, Sugar Land, TX 77479
2154 Dryden Rd, Houston, TX 77030
Sugar Land, TX
5227 Hummingbird St, Houston, TX 77035
Professional information
See more information about EDWARD B RUBENSTEIN at trustoria.com
Ceo, Medical & Commercial Development Solutions Inc
Ceo, Medical & Commercial Development Solutions Inc
Location:
Houston, Texas Area
Industry:
Biotechnology
Compositions For Treating Cancer-Related Fatigue And Methods Of Screening Thereof
Compositions For Treating Cancer-Related Fatigue And Methods Of Screening Thereof
US Patent:
2012023, Sep 20, 2012
Filed:
Sep 13, 2011
Appl. No.:
13/231098
Inventors:
Stephen Sonis - Wayland MA, US
Edward Fey - Boston MA, US
Edward B. Rubenstein - Houston TX, US
Edward Fey - Boston MA, US
Edward B. Rubenstein - Houston TX, US
International Classification:
A61K 31/522, A61P 25/00
US Classification:
51426336
Abstract:
An animal model has been developed based the understanding that a central mechanism in patients with CTRF is that chemotherapy and/or radiation initiates canonical pathways leading to the development of disrupted sleep architecture, resulting in disruption of REM sleep and fatigue and cognitive dysfunction. Drugs that restore the activity patterns and levels towards normal and/or decrease the pro-inflammatory cytokines associated with the disrupted sleep, should be effective in alleviating one or more symptoms of CTRF. Pentoxifylline was demonstrated to improve activity levels in animals treated with etoposide.
Compositions For Treating Cancer-Related Fatigue And Methods Of Screening Thereof
Compositions For Treating Cancer-Related Fatigue And Methods Of Screening Thereof
US Patent:
2013024, Sep 19, 2013
Filed:
May 2, 2013
Appl. No.:
13/886035
Inventors:
Edward G. FEY - Boston MA, US
Edward B. RUBENSTEIN - Houston TX, US
Edward B. RUBENSTEIN - Houston TX, US
Assignee:
Tenera Therapeutics, LLC - Boston MA
International Classification:
A61K 31/522
US Classification:
51426336, 544271
Abstract:
An animal model has been developed based the understanding that a central mechanism in patients with CTRF is that chemotherapy and/or radiation initiates canonical pathways leading to the development of disrupted sleep architecture, resulting in disruption of REM sleep and fatigue and cognitive dysfunction. Drugs that restore the activity patterns and levels towards normal and/or decrease the pro-inflammatory cytokines associated with the disrupted sleep, should be effective in alleviating one or more symptoms of CTRF. Pentoxifylline was demonstrated to improve activity levels in animals treated with etoposide.